Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05128825 · ClinicalTrials.gov registry record · Phase 2
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Phase 2 study of High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer, sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 170
- Enrollment target
- 20
- Study locations
NCT05128825: Recruiting Phase 2 study of High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer, sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals.
NCT05128825 is a Phase 2 study of High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer that is actively recruiting participants, run by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals. The registered enrollment target is 170 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (28% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05128825, a Phase 2 study of High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer, is actively recruiting participants, sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 170 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multi-part Phase 2 study to evaluate the efficacy and safety of azenosertib (ZN-c3) in subjects with Platinum-Resistant, High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Part 2 of the study will be conducted in subjects whose tumors are Cyclin E1 positive as determined by central review using the Sponsor's investigational clinical trial assay.
Primary Outcome
Participants who achieve partial response (PR) or complete response (CR) per RECIST v1.1 criteria.
Conditions Studied
Interventions
- DRUG azenosertib
Study Locations (20)
Florida
- Site 0239 - Florida Cancer Specialists - East - Daytona Beach
- Site 0173 - Mount Sinai Medical Center - Miami Beach
- Site 0308 - Advent Health - Orlando
Massachusetts
- Site 0221 - Tufts Medical Center - PPDS - Boston
- Site 0104 - Dana Farber Cancer Institute - Boston
- Site 0307 - Lahey Hospital and Medical Center - Burlington
Arizona
- Site 0143 - HonorHealth - Phoenix
- Site 0102 - University of Arizona Cancer Center - Tucson
California
- Site 0258 - UC San Diego Moores Cancer Center - La Jolla
- Site 0287 - Ridley Tree Cancer Center - Santa Barbara
Georgia
- Site 0108 - Emory University Hospital - Atlanta
- Site 0236 - Memorial Health - Savannah
Indiana
- Site 0284 - Community Cancer Center North - Indianapolis
- Site 0217 - St Vincent Hospital and Health Care Centers - Indianapolis
Alabama
- Site 0170-USA Mitchell Cancer Institute - Mobile
Colorado
- Site 0135 - Rocky Mountain Cancer Centers - Lone Tree
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2022-02-17 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 2 |
What NCT05128825 shows while recruiting
NCT05128825 is an interventional study that assigns participants to a tested intervention. The registered 170 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (28% higher).
The record links to 1 condition, with High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer appearing as the primary indexed condition, and to 1 intervention - of which azenosertib is the first listed.
NCT05128825 names 20 study sites across 12 states, led by Florida, Massachusetts, Arizona.
Frequently Asked Questions
What is clinical trial NCT05128825 about?
NCT05128825 is a clinical study titled "A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer". This is a multi-part Phase 2 study to evaluate the efficacy and safety of azenosertib (ZN-c3) in subjects with Platinum-Resistant, High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Part 2 of the study will be conducted in subjects whose tumors are Cyclin E1 positive as determi...
What is the current status of trial NCT05128825?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 170 participants. The study started on 2022-02-17. Estimated completion is 2027-06-30.
What conditions does trial NCT05128825 study?
This clinical trial studies the following conditions: High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
What interventions are being tested in trial NCT05128825?
The interventions under investigation include: azenosertib (DRUG).
Who is sponsoring clinical trial NCT05128825?
This trial is sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05128825 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05128825's enrollment target sits among peer trials
170 399th of 2000 higher than 1,599 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02016430 · 170 participants · NA
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
- NCT02621021 · 170 participants · Phase 2
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- NCT04094701 · 170 participants · NA
Hip Arthroscopy Postoperative Opioid Demands
- NCT04166409 · 170 participants · Phase 3
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI